Lisata Therapeutics

Name

Lisata Therapeutics

Legal name

Lisata Therapeutics, Inc.

Website

https://lisata.com

Company type

Public

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Clinical-stage oncology biopharmaceutical

NAICS

Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Lead Optimization & Preclinical Candidate Selection (HLAIALAB)

akta.pro secondary industry

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)

Keywords

• Clinical-stage biopharmaceutical
• Tumor-targeted drug delivery
• Oncology therapeutics pipeline
• Cell therapy development
• Cardiovascular regenerative medicine

Headquarters

HQ city

Basking Ridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Licensing and Milestone Payments: Pre-revenue clinical stage company. Revenue potential from licensing agreements with partners like Catalent (ADC technology) and milestone payments upon achievement of clinical and regulatory milestones.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Lisata Therapeutics is a clinical-stage biopharmaceutical company developing investigational therapies for advanced solid tumors and serious cardiovascular diseases. Its lead product candidate, certepetide (LSTA1), is a cyclic peptide that selectively enhances the delivery of anti-cancer drugs into solid tumors and is being evaluated in Phase 2 trials for pancreatic cancer, cholangiocarcinoma, and other gastrointestinal tumors under the proprietary CendR Platform®. The company also advances a portfolio of autologous CD34+ cell therapy product candidates (XOWNA, HONEDRA, LSTA201, OLOGO) for cardiovascular indications such as coronary microvascular dysfunction, critical limb ischemia, diabetic kidney disease, and refractory angina.

Product overview

Lisata Therapeutics is a clinical-stage pharmaceutical company developing a portfolio of innovative therapies for advanced solid tumors and other serious diseases. The company's core product is certepetide (LSTA1), a cyclic peptide drug candidate in Phase 2 trials for multiple solid tumor types including pancreatic ductal adenocarcinoma and cholangiocarcinoma. This product is powered by the proprietary CendR Platform technology, which enables targeted penetration of anti-cancer drugs into solid tumors. The company also operates a separate CD34+ Cell Technology platform for cardiovascular applications, with product candidates including XOWNA (LSTA16) for coronary microvascular dysfunction, HONEDRA (LSTA12) for critical limb ischemia in Japan, LSTA201 for diabetic kidney disease, and OLOGO (LSTA14) for refractory angina. Multiple clinical trials are underway including BOLSTER (cholangiocarcinoma), ASCEND (pancreatic cancer), FORTIFIDE (pancreatic cancer), and CENDIFOX (multiple GI cancers).

Differentiator

Problem solved

Functional benefit

Products and services

• Certepetide (LSTA1) Certepetide (LSTA1) is an investigational cyclic peptide drug candidate designed to selectively target and enhance the uptake of anti-cancer drugs into solid tumors. It is being evaluated in Phase 2 clinical trials for metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, and other gastrointestinal cancers.
• CendR Platform® The CendR Platform® is a proprietary targeted penetration technology that enables more effective tumor-targeted, tissue-penetrating delivery of anti-cancer drugs to advanced solid tumors, and can also target non-cancerous immunosuppressive cells within tumors to enable a patient's immune system and immunotherapies to fight cancer more effectively. It is the foundation technology for certepetide and the basis of the Catalent ADC license agreement.
• CD34+ Cell Technology CD34+ Cell Technology is a cell-based therapy platform using bone marrow-derived CD34+ cells for therapeutic angiogenesis in ischemic conditions. The platform underpins multiple cardiovascular product candidates including XOWNA, HONEDRA, LSTA201, and OLOGO.
• XOWNA® (LSTA16) XOWNA® (LSTA16) is an investigational CD34+ cell therapy product candidate for the treatment of Coronary Microvascular Dysfunction (CMD) in the United States.
• HONEDRA® (LSTA12) HONEDRA® (LSTA12) is an investigational CD34+ cell therapy product candidate for the treatment of Critical Limb Ischemia (CLI) in Japan.
• LSTA201 LSTA201 is an investigational CD34+ cell therapy product candidate for the treatment of Diabetic Kidney Disease (DKD).
• OLOGO™ (LSTA14) OLOGO™ (LSTA14) is an investigational CD34+ cell therapy product candidate for the treatment of No-Option Refractory Disabling Angina (NORDA) in the United States.

Quantifiable outcome

• Positive Phase 2b results in metastatic pancreatic cancer reported in clinical trials
• +1 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core and strategic.

• CatalentcoreTechnology or Integration · 9 October 2025Global license agreement allowing Catalent to evaluate and develop antibody-drug conjugates (ADCs) using Lisata's certepetide cyclic peptide with Catalent's SMARTag® platform. Catalent has worldwide rights to incorporate certepetide into multiple ADCs targeting difficult-to-treat diseases. Deal includes milestone payments and revenue sharing.
• GATC HealthstrategicTechnology or Integration · 1 January 2025Partnership applying AI-driven multiomics technology to drug development. GATC Health uses its Multiomics Advanced Technology (MAT) AI platform to simulate human biology and model drug-disease interactions. Expanded from earlier cardiovascular collaboration to opioid use disorder drug development.
• Australasian Gastro-Intestinal Trials Group (AGITG)strategicStrategic or Co-development PartnerCo-funded collaboration with NHMRC Clinical Trial Centre at University of Sydney for ASCEND Phase 2b trial of certepetide in metastatic pancreatic cancer in Australia and New Zealand.
• University of Kansas Medical CenterstrategicStrategic or Co-development PartnerInvestigator-initiated CENDIFOX Phase 1b/2 trial of certepetide for pancreatic, colon, and appendiceal cancers.
• WARPNINE, Inc.strategicStrategic or Co-development PartnerRegistered charity in Australia funding iLSTA Phase 1 trial evaluating certepetide with durvalumab, gemcitabine and nab-paclitaxel in locally advanced pancreatic cancer.
• Cend TherapeuticscoreStrategic or Co-development PartnerSource company whose CendR Platform™ technology was central to the 2022 merger that created Lisata Therapeutics. Caladrius Biosciences and Cend Therapeutics completed an all-stock merger to form the new company focused on Cend's tumor-penetrating platform.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Nanobiotix: Clinical-stage developer of nanoparticle-based therapeutics designed to penetrate and disrupt solid tumors via physics-based mechanisms (radioenhancement). Most directly comparable to Lisata on the proprietary tumor-targeted delivery thesis for advanced solid tumors.
• Celsion Corporation: Clinical-stage oncology company developing heat-activated liposomal drug delivery (ThermoDox) for solid tumors including pancreatic and liver cancers. Directly comparable to Lisata on the tumor-penetrating drug delivery approach and pancreatic cancer focus.
• Plus Therapeutics: Clinical-stage company developing targeted radiopharmaceuticals for difficult-to-treat solid tumors. Comparable to Lisata as a small-cap oncology platform developing delivery technologies intended to overcome the limitations of conventional systemic therapy in solid tumors.
• Diffusion Pharmaceuticals: Clinical-stage company developing trans sodium crocetinate (TSC) to enhance oxygen diffusion and improve drug delivery in solid tumors. Comparable to Lisata in tackling the same fundamental problem — limited chemotherapy penetration into solid tumor tissue.
• Genprex: Clinical-stage gene therapy company focused on solid tumors (e.g., lung, pancreatic) using a tumor-targeted gene delivery platform. Comparable as a small-cap oncology company developing a delivery-platform approach for high-unmet-need solid tumor indications.
• Lineage Cell Therapeutics: Clinical-stage cell therapy company developing allogeneic cell transplant therapies including stem cell-derived candidates. Comparable to Lisata's CD34+ cell therapy arm and overall small-cap clinical-stage profile.

Emerging players

• Magenta Therapeutics: Clinical-stage company developing hematopoietic stem cell (HSC)-targeted therapies for transplant, gene therapy, and immune reset indications. Directly comparable to Lisata's CD34+ HSC-derived cell therapy platform for cardiovascular applications.

Broad incumbents

• Mesoblast: Commercial/clinical-stage cell therapy company developing mesenchymal stem cell (MSC)-based therapies across inflammatory and cardiovascular indications. Broader, larger-scope cell therapy comparable to Lisata's CD34+ cardiovascular pipeline.
• Bristol-Myers Squibb: Large oncology incumbent with broad solid tumor portfolio including pancreatic and biliary tract cancer programs, plus Opdivo-based immunotherapy combinations relevant to certepetide's mechanism of enhancing immunotherapy penetration.
• Ipsen: Specialty oncology incumbent with a pancreatic and biliary tract cancer franchise (Onivyde). Comparable to Lisata on focus in advanced solid tumors of the GI tract — relevant board-level overlap (former Ipsen NA President Cynthia Flowers is on Lisata's board).

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/lisata_tx
• Facebookfacebook.com/LisataTherapeutics
• LinkedInlinkedin.com/company/lisatatherapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds12 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A7 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lisata Therapeutics